The Safety and Efficiency of Tirofiban in Acute Ischemic Stroke Patients Treated with Mechanical Thrombectomy: A Multicenter Retrospective Cohort Study
Table 1
Demographic and clinical characteristics of the subjects.
Characteristic
Tirofiban group N = 89
Control group N = 85
value
Sex (male)
59 (66.3)
43 (50.6)
0.036
Age, median (IQR), y
68 (56.5–75.0)
68 (54.5–77.0)
0.640
Smoking
25 (28.1)
12 (14.1)
0.024
Drinking
17 (19.1)
9 (10.6)
0.115
Hypertension
50 (56.2)
35 (41.2)
0.048
T2DM
24 (27.0)
17 (20.0)
0.279
Coronary atherosclerotic disease
27 (30.3)
26 (30.6)
0.971
Atrial fibrillation
26 (29.2)
51 (60.0)
0.000
Previous TIA/stroke
17 (19.1)
11 (12.9)
0.269
NIHSS on admission, median (IQR), point
15 (12.0–21.0)
16 (13.0–20.0)
0.452
ASPECTS/pc-ASPECT, median (IQR), point
10 (9.0–10.0)
10 (8.3–10.0)
0.456
Glucose, median (IQR), mmol/l
7.2 (6.2–9.4)
7.2 (5.9–9.0)
0.457
PLT, median (IQR), ×109/L
192 (147.2–236.7)
177 (144.0–213.3)
0.142
INR, median (IQR), s
1.03 (0.95–1.11)
1.05 (0.99–1.14)
0.064
TOAST
Large artery atherosclerosis
68 (76.4)
41 (48.2)
0.000
Cardioembolism
21 (23.6)
44 (51.8)
0.000
Location of stroke
Anterior circulation stroke
69 (77.5)
67(78.8)
0.836
Posterior circulation stroke
20 (22.5)
18(21.2)
0.836
Median SBP in 24 h, median (IQR), mmHg
130 (118.0–145.0)
130 (121.3–140.0)
0.926
Premorbid antiplatelets
17 (19.1)
11 (12.9)
0.269
Premorbid anticoagulants
4 (4.5)
11 (12.9)
0.047
Data are number, number (%), median (IQR), or mean (SD).
